PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Nephrology, Inkosi Albert Luthuli Central Hospital, Durban, South Africa.\', \'Clinical Operations and Medical Affairs, Sanofi, Midrand, South Africa. celia.bouharati@gmail.com.\', \'Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa.\', \'Department of Health Informatics, Rutgers School of Health Professions, The State University of New Jersey, Newark, New Jersey, United States.\', \'Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.\', \'Faculty of Medicine, Division of Cardiology and Interventional Cardiology, University of Texas Health Science Centre at San Antonio, San Antonio, Texas, United States.\', \'Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.\', \'Department of Paediatrics and Child Health, Tygerberg Hospital, FAMCRU, Stellenbosch University, Cape Town, South Africa.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s00508-021-01851-w
?:doi
?:hasPublicationType
?:journal
  • Wiener klinische Wochenschrift
is ?:pmid of
?:pmid
?:pmid
  • 33837463
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.345
?:rankingScore_hIndex
  • 46
?:title
  • Real-world evidence and product development: Opportunities, challenges and risk mitigation.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all